Integrated Bile Metabolomics and Serum Biomarkers for Differentiating Cholangiocarcinoma from Cholelithiasis
Open Access
- 16 October 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2356
Abstract
Background: We investigated bile metabolites and serum variables for differentiating cholangiocarcinoma (CCA) from cholelithiasis. Methods: Bile from 31 patients with CCA and 48 with cholelithiasis was profiled by high-resolution LC-MS. Candidate metabolites and serum variables were integrated in a seven-variable classifier, and public single-cell data provided tissue-level biological context. Results: Of 2269 annotated metabolite features, 532 met the exploratory screening criteria. The selected signature comprised pyruvic acid, lipoxin A4, CEA, APOA1, 3-chloro-L-tyrosine, ADP-ribose, and glutaric acid; pyruvic acid had the largest contribution in the SHAP analysis. Random forest achieved an AUC of 0.894 in the classifier comparison, a training cross-validation AUC of 0.820, and an AUC of 0.914 in the 16-patient test subset. Because selection used all 79 patients before evaluation, these internal performance estimates may be optimistic. Conclusions: Integrated bile and serum profiling identified a promising seven-variable signature for differentiating CCA from cholelithiasis in this cohort. Added diagnostic value over routine serum markers and performance in other benign biliary conditions have not been established.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC24074)
- Fundamental Research Funds for the Central Universities (lzujbky-2025-it42)
This publication has 36 references indexed in Scilit:
- Endoscopic and novel approaches for evaluation of indeterminate biliary stricturesJournal of the Formosan Medical Association, 2025
- Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancerJournal of Hepatology, 2024
- Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma PathologyThe American Journal of Pathology, 2024
- Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinomaJHEP Reports, 2024
- Phenotypes of Primary Sclerosing Cholangitis and Differential DiagnosisClinics in Liver Disease, 2023
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Metabolic reprogramming in cholangiocarcinomaJournal of Hepatology, 2022
- Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipidsHepatology, 2022
- Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinomaJournal of Hepatology, 2020
- Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysisGastrointestinal Endoscopy, 2015